HIPH (HIPH) Stock Price & Analysis
HIPH (HIPH) rose 12.50% to USD 0 as of July 25, 2026 at 08:00 UTC, according to Nexqual real-time market data.
HIPH last closed at USD 0; the session ranged USD 0–0 on volume of 76,636 shares. Market capitalization is $28.98M, with a 52-week range of USD 0–0 (OID). Source: Nexqual, July 25, 2026 at 08:00 UTC.
Key Statistics (as of July 25, 2026 at 08:00 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 12.50% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 76,636 shares |
| Market Cap | $28.98M |
| Exchange | OID |
Technical Analysis (HIPH)
Nexqual's technical model rates HIPH "STRONG SELL" based on 0 bullish and 4 bearish signals across 124 daily candles, as of July 25, 2026 at 08:00 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 44.1 (neutral) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (HIPH)
Wall Street analysts rate HIPH "None", per Nexqual as of July 25, 2026 at 08:00 UTC.
| Consensus Rating | None |
|---|
Earnings (HIPH)
Source: Nexqual, July 25, 2026 at 08:00 UTC.
Financials & Fundamentals (HIPH)
| Total Revenue | $208,955 |
|---|---|
| Revenue Growth (YoY) | +23882.00% |
| Gross Margin | +123.30% |
| Operating Margin | +5.73% |
| Profit Margin | +0.00% |
| Current Ratio | 0.1 |
| Total Cash | $96,391 |
| Total Debt | $406,089 |
| Free Cash Flow | $599,919 |
Source: Nexqual, July 25, 2026 at 08:00 UTC.
Financial Health Score (HIPH)
Nexqual rates HIPH's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 08:00 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $96K cash, no debt |
| Cash Flow | Strong — FCF $600K, 287% margin |
| Efficiency | Mixed — No data |
Ownership (HIPH)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 64.40B |
Source: Nexqual, July 25, 2026 at 08:00 UTC.
Leadership (HIPH)
HIPH is led by Ryan Fishoff, CEO & Interim Chairman, per Nexqual as of July 25, 2026 at 08:00 UTC.
| CEO & Interim Chairman | Ryan Fishoff |
|---|---|
| President and Director | Robert Rico (age 51) |
| Founder & Director | Alfred Culbreth |
| COO & Director | David Howell |
| President of Sales | Andrew Figueroa |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PURA | Puration Inc. | USD 0 | ▲ 0% |
| EVHO | Evercore Holdings, Inc. | USD 0 | ▼ 2.22% |
| KALY | KALI INC | USD 0 | ▲ 0% |
| HMPQ | HEMP AMERICANA INC | USD 0 | ▲ 0% |
| NOUV | Nouveau Life Pharmaceuticals, I | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 08:00 UTC. This page is informational and not investment advice.